Healthcare
McEnany: ‘Fauci Is One Member Of A Team,’ and His Viewpoint is Given to President Trump
With reports circling about President Trump and infectious disease expert Dr. Anthony Fauci’s strained relationship, White House Press Secretary Kayleigh McEnany explained the situation on “Fox and Friends” Monday morning.
Fauci represents one singular viewpoint in the entire task force, McEnany said. He is tasked with looking at matters from a public health standpoint while other members weigh the economic and social impacts of lockdowns and rules.
“The point of the task force is to be a whole of government look at what is best for this country,” McEnany said. “Dr. Fauci is one member of a team, but rest assured his viewpoint is represented and the information gets to the President through the task force.”
The Press Secretary cited Dr. Elinore McCance-Katz, Assistant Secretary of Health and Human Services for Mental Health and Substance Use, as another member who evaluates the risks of lockdowns with issues like increased suicide and drug overdoses.
The different members have unique perspectives and should be looked at wholistically, instead of just looking at one member’s opinion on the information they have been studying.
Monday’s interview follows reports last week that the President has sidelined Fauci and not been briefed personally by him in two months. McEnany said the information Fauci provides is put before the President, through other Task Force members.
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
-
Featured7 days agoDHS Alert: suspected terrorist on southwest border poses ‘imminent’ national security threat to U.S.
-
Healthcare7 days agoOklahoma Mother Sues School District After Alleged Assault by Trans Student
-
China7 days agoTreasury Department sanctions Chinese companies, Mexican individuals as ‘enablers’ to fentanyl crisis
-
Economy3 days agoNew York City Mayor Eric Adams Proposes Housing Asylum Seekers in Private Homes
